CD274 and cancer: The predictive roles of PD-L1+ MDSCs as a biomarker for anti-PD-(L)1 immunotherapy is less studied, although it has been shown that cancer patients with high baseline levels of circulating PMN-MDSC or M-MDSCs respond better to anti-PD-1 immunotherapy treatment [191,198].